HEALTH PROFESSIONAL · SOURCE READING

Addition of an FLT3 inhibitor

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Newly Diagnosed AML / Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML / Chemotherapy

Variants in the tyrosine kinase domain (TKD) and internal tandem duplications (ITD) of the FLT3 gene are frequent in AML and are often associated with an inferior outcome.

Continue within this section

Midostaurin →Quizartinib →

Preserved source evidence · Not medical advice